Literature DB >> 16323009

Activation of cryptic splice sites is a frequent splicing defect mechanism caused by mutations in exon and intron sequences of the OPA1 gene.

Simone Schimpf1, Simone Schaich, Bernd Wissinger.   

Abstract

Mutations in OPA1 are the most frequent cause underlying autosomal dominant optic atrophy (adOA). Until now only few putative splicing mutations in the OPA1 gene have been investigated at the mRNA level and all these result in exon skipping. Here, we report the identification and cDNA analysis of four intronic and three exonic OPA1 gene mutations that cause a variety of splicing defects including activation of cryptic splice sites in either flanking exon or intron sequences, and a leaky splicing mutation. Our results show that cDNA analysis is of prime importance for the full evaluation of the effect of putative splicing mutations in the OPA1 gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16323009     DOI: 10.1007/s00439-005-0096-7

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  8 in total

1.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences.

Authors:  M Krawczak; J Reiss; D N Cooper
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

2.  OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance.

Authors:  U E Pesch; B Leo-Kottler; S Mayer; B Jurklies; U Kellner; E Apfelstedt-Sylla; E Zrenner; C Alexander; B Wissinger
Journal:  Hum Mol Genet       Date:  2001-06-15       Impact factor: 6.150

3.  Sporadic optic atrophy due to synonymous codon change altering mRNA splicing of OPA1.

Authors:  P Amati-Bonneau; L Pasquier; E Lainey; M Ferré; S Odent; Y Malthièry; D Bonneau; P Reynier
Journal:  Clin Genet       Date:  2005-01       Impact factor: 4.438

4.  A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy.

Authors:  Dawn L Thiselton; Christiane Alexander; Jan-Willem Taanman; Simon Brooks; Thomas Rosenberg; Hans Eiberg; Sten Andreasson; Nicole Van Regemorter; Francis L Munier; Anthony T Moore; Shomi S Bhattacharya; Marcela Votruba
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-06       Impact factor: 4.799

Review 5.  [Hereditary optic atrophy].

Authors:  B Lorenz
Journal:  Ophthalmologe       Date:  1994-12       Impact factor: 1.059

6.  Mutation spectrum and splicing variants in the OPA1 gene.

Authors:  C Delettre; J M Griffoin; J Kaplan; H Dollfus; B Lorenz; L Faivre; G Lenaers; P Belenguer; C P Hamel
Journal:  Hum Genet       Date:  2001-10-30       Impact factor: 4.132

7.  Variant phenotypes of incomplete achromatopsia in two cousins with GNAT2 gene mutations.

Authors:  Thomas Rosenberg; Britta Baumann; Susanne Kohl; Eberhart Zrenner; Arne Lund Jorgensen; Bernd Wissinger
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

8.  Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy.

Authors:  Olivier Baris; Cécile Delettre; Patrizia Amati-Bonneau; Marie-Odile Surget; Jean-François Charlin; Antoine Catier; Laurence Derieux; Jean-Laurent Guyomard; Hélène Dollfus; Philippe Jonveaux; Carmen Ayuso; Irene Maumenee; Birgit Lorenz; Shehla Mohammed; Yves Tourmen; Dominique Bonneau; Yves Malthièry; Christian Hamel; Pascal Reynier
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

  8 in total
  9 in total

1.  Loss of exon identity is a common mechanism of human inherited disease.

Authors:  Timothy Sterne-Weiler; Jonathan Howard; Matthew Mort; David N Cooper; Jeremy R Sanford
Journal:  Genome Res       Date:  2011-07-12       Impact factor: 9.043

2.  Multiethnic involvement in autosomal-dominant optic atrophy in Singapore.

Authors:  J L Loo; S Singhal; A V Rukmini; S Tow; P Amati-Bonneau; V Procaccio; D Bonneau; J J Gooley; P Reynier; M Ferré; D Milea
Journal:  Eye (Lond)       Date:  2016-11-18       Impact factor: 3.775

Review 3.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 4.  Mitochondrial Membrane Dynamics and Inherited Optic Neuropathies.

Authors:  Eleni Bagli; Anastasia K Zikou; Niki Agnantis; Georgios Kitsos
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

5.  Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Authors:  Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2006-09-08       Impact factor: 16.971

6.  Neutrophil extracellular trap formation requires OPA1-dependent glycolytic ATP production.

Authors:  Poorya Amini; Darko Stojkov; Andrea Felser; Christopher B Jackson; Carolina Courage; André Schaller; Laurent Gelman; Maria Eugenia Soriano; Jean-Marc Nuoffer; Luca Scorrano; Charaf Benarafa; Shida Yousefi; Hans-Uwe Simon
Journal:  Nat Commun       Date:  2018-07-27       Impact factor: 14.919

7.  Dominant optic atrophy in Denmark - report of 15 novel mutations in OPA1, using a strategy with a detection rate of 90%.

Authors:  Gitte J Almind; Jakob Ek; Thomas Rosenberg; Hans Eiberg; Michael Larsen; Lucamp Lucamp; Karen Brøndum-Nielsen; Karen Grønskov
Journal:  BMC Med Genet       Date:  2012-08-02       Impact factor: 2.103

Review 8.  Inherited mitochondrial optic neuropathies.

Authors:  P Yu-Wai-Man; P G Griffiths; G Hudson; P F Chinnery
Journal:  J Med Genet       Date:  2008-11-10       Impact factor: 6.318

9.  High-resolution en face images of microcystic macular edema in patients with autosomal dominant optic atrophy.

Authors:  Kiyoko Gocho; Sachiko Kikuchi; Takenori Kabuto; Shuhei Kameya; Kei Shinoda; Atsushi Mizota; Kunihiko Yamaki; Hiroshi Takahashi
Journal:  Biomed Res Int       Date:  2013-11-28       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.